Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. ...
Zhongchao Inc. (NASDAQ: ZCMD) is a healthcare-focused platform-based company headquartered in Shanghai, China, founded in 2012. The company serves healthcare professionals, nurses, doctors, and healthcare organizations, as well as patients, primarily through online and app-based channels and supporting patient-management technology. Its core offering is commonly described as healthcare information, education, ...Zhongchao Inc. (NASDAQ: ZCMD) is a healthcare-focused platform-based company headquartered in Shanghai, China, founded in 2012. The company serves healthcare professionals, nurses, doctors, and healthcare organizations, as well as patients, primarily through online and app-based channels and supporting patient-management technology. Its core offering is commonly described as healthcare information, education, and training delivered under the MDMOOC brand, complemented by services that support disease management—particularly in oncology and other major/rare disease contexts.
Business model and segments: Zhongchao operates through two main business lines. First is MDMOOC services, which provide healthcare education and training content (including online and onsite training, clinical practice training, interactive case studies, academic conferences/workshops, continuing education courses, and multimedia educational articles/video). The platform is accessible through channels such as a mobile app, a WeChat subscription account, and a web platform, aiming to reach medical professionals and institutional customers.
Second, the company has a line described as sales of patented drugs. This indicates a dual approach: (i) recurring or service-oriented engagement via education/training and digital healthcare assistance, and (ii) product-oriented involvement through patented drug sales.
Products and services: In addition to educational content, Zhongchao provides patient management services via an IT system under related brand names (e.g., Zhongxun) and WeChat mini programs. These offerings are designed to facilitate care coordination and disease management workflows for pharmaceutical enterprises and healthcare-related non-profit organizations and institutions, including hospitals, medical associations, medical institutions, medical journals, and medical foundations.
Customer and go-to-market: The company’s customers span both pharma/healthcare ecosystem stakeholders (pharmaceutical enterprises and institutional organizations) and end users within the healthcare system (healthcare professionals and caregivers). This positioning suggests that it monetizes through B2B/B2B2C partnerships (e.g., education/training and patient-management support for pharma and institutions) as well as through ongoing platform usage.
Cost and BOM considerations (conceptual): As a digital health and education platform, Zhongchao’s “bill of materials” is typically dominated by technology/platform operations, content creation and clinical/educator support, customer success and sales/marketing, and compliance/administrative overhead required for healthcare-related services. Direct physical logistics and large inventory burdens are generally less central than in traditional manufacturing businesses; however, the patented drug sales line introduces product-related costs and working-capital dynamics.
Financial and risk context (high level): The provided TTM financial indicators in the source show profitability metrics that appear negative (e.g., operating/net margin figures reported as negative), while liquidity ratios appear strong (e.g., high current/quick ratios). For investors, the key considerations usually include platform adoption and retention, content and service monetization effectiveness, scalability of patient-management tools, the sustainability of the patented-drug business line, and ongoing cost discipline.
Key people: The company is led by founder and CEO Weiguang Yang (also described as Chairman, President & CEO in the provided materials). The provided materials also list Pei Xu as CFO, Secretary, and Director.
Overall, Zhongchao’s strategy centers on leveraging an online medical education and digital healthcare platform to serve the oncology and broader healthcare needs of both professionals and patients in China, supported by patient-management technology and additional revenue from patented drug sales.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$11.4M
-28.3%
+3.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-6.3M
-881.0%
-453.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+42.5%
-24.4%
-18.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-54.4%
-2430.3%
-485.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-55.5%
-1268.2%
-437.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$692830
+115.3%
-162.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+6.1%
+121.4%
-160.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.1%
-49.3%
+2.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
11.11x
-9.1%
+36.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
